Application of dimethyldiguanide as active component in medicine for treating disc degeneration disease
A technology of metformin and active ingredients is applied in the application field of active ingredients in drugs for the treatment of intervertebral disc degenerative diseases, and can solve the problems of not using intervertebral disc degeneration and the like
Inactive Publication Date: 2016-11-23
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF2 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0003] At present, the medical use of metformin is mainly concentrated on type II diabetes. Although it has also bee
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Login to View More
PUM
Login to View More
Abstract
The invention discloses an application of dimethyldiguanide as an active component in a medicine for treating a disc degeneration disease. The application of the dimethyldiguanide to a product for treating and delaying the animal disc degeneration disease is a medical new application of the dimethyldiguanide as a medicine, which indicates that the dimethyldiguanide has a good effect for treating the disc degeneration disease.
Description
technical field [0001] The invention relates to the field of biotechnology, in particular to the application of metformin as an active ingredient in a drug for treating degenerative disc disease. Background technique [0002] Metformin is currently one of the most widely used oral hypoglycemic agents in the world, and has been used in clinical practice for more than 50 years. Metformin has good monotherapy / combination therapy efficacy and safety evidence, and good health economics benefit evidence. Whether it is for blood sugar control or the prevention of cardiovascular complications of diabetes, it has clear clinical evidence. Therefore, the drug has become the core drug for controlling diabetes in the world. In my country, metformin has been used for nearly 20 years. In 1995, the FDA officially approved metformin for the treatment of type II diabetes (T2DM), and in 2004 the European Union officially approved metformin for the treatment of T2DM in children over 10 years...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More
IPC IPC(8): A61K31/155A61P19/08
CPCA61K31/155
Inventor 张小磊陈德横徐华梓
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com